阿托伐他汀的药理作用分析与控制血脂水平的临床疗效研究

目的总结阿托伐他汀的药理作用,探讨阿托伐他汀治疗冠心病高脂血症的疗效及机制。方法 120例患者随机分成观察组和对照组,两组均进行基础治疗,观察组同期加用阿托伐他汀,20mg/d,1次/d。对照组同期加用辛伐他汀,20mg/d,1次/d,疗程均为4周。治疗前后测定两组患者血脂水平与BNP浓度。结果治疗后与治疗前比较,两组TC、TG和LDL-C水平明显降低,HDL-C明显升高,尤其观察组明显（P〈0.05）;治疗后,观察组TC、TG、LDL-C和HDL-C水平与对照组比较,差异有统计学意义（P〈0.05）。两组治疗后BNP浓度明显降低,与治疗前比较差异有统计学意义（P均〈0.05）,且观察组较对照组降低更明显（P〈0.05）。观察组不良反应发生率为2/60（3.33%）,对照组为3/60（5%）,两组不良反应发生率差异无统计学意义（P〉0.05）。结论阿托伐他汀能够降低血脂水平,是治疗冠心病合并高脂血症安全有效的药物。

Clinical Study of the Atorvastatin Pharmacological Effects and the Efficacy of Control Lipid Levels

Objective To summarize the pharmacological effects of atorvastatin,explore atorvastatin treatment efficacy and mechanism of coronary heart disease hyperlipidemia.Methods 120 patients were randomly divided into the observation group and the control group,the two groups were given the basis treatment,in the same period,the observation group plus the atorvastatin 20 mg/d,1 time/d.Over the same period,the control group plus simvastatin 20 mg/d,1/d,the course was 4 weeks.Determine the lipid levels and BNP concentration in the two groups of patients before and after treatment.Results After treatment,compared with before treatment,the TC,TG and LDL-C levels of the two groups were significantly lower,HDL-C was significantly higher,observation group were especially significantly（P0.05）;After treatment,the differences of the TC,TG,LDL-C and HDL-C levels between the observation group and the control group were significant（P0.05）.BNP levels significantly reduced after treatment in both groups,the difference was statistically significant（P0.05）,compared with before treatment,and the BNP in the observation group decreased significantly than in the control group（P0.05）.The incidence of adverse reactions in the observation group was 2/60（3.33%）,3/60（5%）in the control group,the incidence of adverse reactions was no significant difference between the two groups（P 0.05）.Conclusion Atorvastatin can be able to reduce blood lipid levels which is a safe and effective drug to treat coronary heart disease combined hyperlipidemia.